Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Vertex Pharmaceutic (VRTX)

Vertex Pharmaceutic (VRTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 114,719,208
  • Shares Outstanding, K 254,034
  • Annual Sales, $ 12,001 M
  • Annual Income, $ 3,953 M
  • EBIT $ 4,173 M
  • EBITDA $ 4,383 M
  • 60-Month Beta 0.31
  • Price/Sales 9.79
  • Price/Cash Flow 26.31
  • Price/Book 6.29

Options Overview Details

View History
  • Implied Volatility 32.26% (-0.66%)
  • Historical Volatility 40.94%
  • IV Percentile 60%
  • IV Rank 40.55%
  • IV High 47.19% on 04/08/25
  • IV Low 22.08% on 08/27/25
  • Expected Move (DTE 1) 4.72 (1.04%)
  • Put/Call Vol Ratio 0.90
  • Today's Volume 1,573
  • Volume Avg (30-Day) 3,627
  • Put/Call OI Ratio 0.72
  • Today's Open Interest 51,889
  • Open Int (30-Day) 50,296
  • Expected Range 448.98 to 458.42

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 33 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate 3.91
  • Number of Estimates 7
  • High Estimate 4.37
  • Low Estimate 3.51
  • Prior Year 3.55
  • Growth Rate Est. (year over year) +10.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
449.80 +1.51%
on 03/19/26
507.92 -10.11%
on 03/10/26
-12.70 (-2.71%)
since 02/19/26
3-Month
429.00 +6.43%
on 01/20/26
507.92 -10.11%
on 03/10/26
+0.37 (+0.08%)
since 12/19/25
52-Week
362.50 +25.95%
on 08/11/25
515.67 -11.46%
on 03/20/25
-55.95 (-10.92%)
since 03/19/25

Most Recent Stories

More News
Q4 Earnings Outperformers: Vertex Pharmaceuticals (NASDAQ:VRTX) And The Rest Of The Therapeutics Stocks

Q4 Earnings Outperformers: Vertex Pharmaceuticals (NASDAQ:VRTX) And The Rest Of The Therapeutics Stocks

VRTX : 458.70 (+1.57%)
1 Momentum Stock to Research Further and 2 We Ignore

1 Momentum Stock to Research Further and 2 We Ignore

TH : 9.11 (-0.87%)
PNTG : 32.33 (-2.80%)
VRTX : 458.70 (+1.57%)
2 Reasons to Watch VRTX and 1 to Stay Cautious

2 Reasons to Watch VRTX and 1 to Stay Cautious

VRTX : 458.70 (+1.57%)
Stocks making big moves yesterday: nLIGHT, Myriad Genetics, Vertex Pharmaceuticals, Nextpower, and Teladoc

Stocks making big moves yesterday: nLIGHT, Myriad Genetics, Vertex Pharmaceuticals, Nextpower, and Teladoc

TDOC : 5.51 (+1.66%)
LASR : 70.50 (+2.86%)
MYGN : 4.74 (+2.16%)
VRTX : 458.70 (+1.57%)
NXT : 117.88 (+2.17%)
S&P Futures Waver as Middle East Conflict Uncertainty Persists, U.S. Inflation Data in Focus

March S&P 500 E-Mini futures (ESH26) are trending down -0.09% this morning, swinging between gains and losses as uncertainty surrounding the Middle East conflict remains high, while investors await key...

DDOG : 129.29 (-1.50%)
VRTX : 458.70 (+1.57%)
ORCL : 155.29 (+1.56%)
NKE : 53.40 (-0.13%)
TRI : 92.97 (-0.99%)
UNF : 265.45 (-0.85%)
ESH26 : 6,613.75 (-0.18%)
OXY : 59.60 (+2.09%)
APA : 37.83 (+3.33%)
0QWI.LN : 50.380 (-2.53%)
AVAV : 210.60 (-2.43%)
FANG : 190.14 (+0.24%)
US stocks hold steadier as Wall Street waits for the next signal on how long war with Iran may last

U.S. stocks held steadier as Wall Street waited for the next signal on when the war with Iran may end

$SPX : 6,614.56 (-0.15%)
VRTX : 458.70 (+1.57%)
WST : 241.11 (+0.88%)
$DOWI : 46,074.60 (-0.33%)
KSS : 12.91 (+7.32%)
$IUXX : 24,391.92 (-0.14%)
Why Vertex Pharmaceuticals (VRTX) Stock Is Up Today

Why Vertex Pharmaceuticals (VRTX) Stock Is Up Today

VRTX : 458.70 (+1.57%)
Vertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Povetacicept in Adults With IgA Nephropathy

- For the primary endpoint, patients treated with povetacicept achieved a 52.0% reduction from baseline in proteinuria as measured by 24-hour urine protein to creatinine ratio (UPCR) and achieved...

VRTX : 458.70 (+1.57%)
Vertex to Participate in Upcoming March Investor Conferences

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in two upcoming investor conferences. Charlie Wagner, Chief Operating and...

VRTX : 458.70 (+1.57%)
Vertex to Present New Data on JOURNAVX® That Demonstrates Effective Pain Management Following Aesthetic and Reconstructive Procedures

-Over 90% of patients in the study were opioid free through the end of multimodal treatment with JOURNAVX- -These data have been accepted for oral presentation at the...

VRTX : 458.70 (+1.57%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Vertex Pharmaceuticals Incorporated is focused on the discovery, development, and commercialization of small molecule drugs targeting serious diseases. The company's main area of focus is cystic fibrosis. The company's lead marketed products are Trikafta, Symdeko/Symkevi, Orkambi and Kalydeco, which...

See More

Key Turning Points

3rd Resistance Point 472.86
2nd Resistance Point 468.41
1st Resistance Point 460.00
Last Price 458.62
1st Support Level 447.14
2nd Support Level 442.69
3rd Support Level 434.28

See More

52-Week High 515.67
Last Price 458.62
Fibonacci 61.8% 457.16
Fibonacci 50% 439.08
Fibonacci 38.2% 421.01
52-Week Low 362.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar